PET
0.019
171.4%
STP
0.265
-44.2%
CKA
0.073
69.8%
VBS
0.11
-37.1%
A1G
0.52
65.1%
IPB
0.006
-33.3%
APC
0.015
50%
NAE
0.002
-33.3%
AYT
0.006
50%
SFG
0.002
-33.3%
ERA
0.003
50%
OVT
0.005
-28.6%
RMY
0.045
45.2%
VUL
4.41
-27.5%
TCG
0.75
38.9%
IMI
0.011
-26.7%
QFE
0.081
37.3%
CTN
0.003
-25%
PNN
0.12
36.4%
MAY
0.009
-25%
DAL
0.054
35%
RKB
0.003
-25%
DMG
0.008
33.3%
NFM
0.016
-23.8%
FBR
0.004
33.3%
EPI
1.005
-23.3%
MRQ
0.004
33.3%
IBX
0.02
-23.1%
BDG
0.08
29%
RML
0.053
-22.1%
MGA
0.081
28.6%
AUR
0.018
-21.7%
NES
0.009
28.6%
LMG
0.023
-20.7%
GR8
0.205
28.1%
AKN
0.004
-20%
EDU
0.77
27.3%
FCT
0.008
-20%
PKY
0.019
26.7%
GLL
0.008
-20%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

LTR Pharma (ASX:LTP) indicates first patients have received SPONTAN® under TGA Scheme

LTR Pharma (ASX:LTP) has announced that the first patients have received SPONTAN®, a nasal spray treatment for erectile dysfunction (ED), under the Therapeutic Goods Administration (TGA) Special Access Scheme. 

  • First patients receive SPONTAN® under the TGA Special Access Scheme
  • Demonstrates potential for SPONTAN® in an unmet fast-acting, on-demand erectile dysfunction treatment market
  • Internationally recognised Key Opinion Leader now actively engaged in prescribing SPONTAN®
    • Enables strategic market introduction and collection of real-world data
    • Platform to share experiences at international conferences and scientific publications.

LTR Pharma Chairman, Lee Rodne said: “The use of SPONTAN® under the early access program marks a watershed moment for LTR Pharma. It demonstrates both the urgent need for fast-acting ED medication and SPONTAN’s potential to address a high unmet need for a fast and on-demand ED treatment and allows for hands-on, real-world experience with SPONTAN®.”